Background: p53 is a tumour suppressor protein that is involved in many cancer-
| INTRODUCTION
The human mitochondrial genome is highly mutated in colorectal cancer (CC) cells. Somatic substitutions, as well as insertions and deletions, are frequently observed in CC mitogenomes. 1 Although somatic indels (mainly single nucleotide changes) occur predominantly in mononucleotide repeat regions, somatic substitutions target different mitochondrial (mtDNA) positions. 1 Previously, we have suggested that somatic mutations are induced by oxidative stress and accumulate in CC mitogenomes as a result of the relaxation of negative selection constraints. 1 It is possible that somatic mitochondrial (mtDNA) mutations are fixed in CC cells because of inefficient mtDNA repair mechanisms. The key molecule responsible for mtDNA replication and repair is a polymerase gamma (POLG). 2 Nevertheless, our previous study excluded the possibility that somatic mtDNA mutations arose in CC cells as a result of POLG gene mutations. 3 Thus, it remains to be determined whether other genes involved in mtDNA repair are associated with the accumulation of somatic mtDNA mutations in CC cells.
Recently, an essential role in mitochondrial DNA maintenance was reported for the p53 protein. Indeed, it was shown that p53 localizes in mitochondria and forms a complex with POLG and mitochondrial transcription factor A (TFAM), which ensures mitochondrial genomic stability. 4 It was also observed that p53 may participate in the repair of mtDNA damage by base excision repair (BER), 5 which is essential for preventing the incorporation of nucleotide substitutions.
p53 is a transcription factor that can regulate the expression of genes participating in mitochondrial quality control checks. For example, genes encoding TFAM 6 or spermatogenesis associated 18
protein (SPATA18) 7 were found to be the transcriptional targets for p53. Although TFAM functions as a mitochondrial transcription factor, which also plays an important role in mtDNA replication and repair, [8] [9] [10] [11] the SPATA18 mediates the repair or elimination of dysfunctional mitochondria in response to mitochondrial damage. 7, 12 Thus, when p53 is inactivated, the TFAM and SPATA18 pathways cannot function properly, which may lead to accumulation of mtDNA mutations. In consequence, high levels of reactive oxygen species (ROS) may be generated. Subsequently, this specific phenotype could contribute to further mitochondrial and nuclear genome mutagenesis. was applied in our previous study, in which we described mitogenome sequence variability in CC patients from the Polish population. 1 In the present study, the same samples used for the above mentioned study were used to investigate the associations between TP53 gene variability and mitogenome mutagenesis in CC cells. The same DNA isolates used for TP53 amplification were previously used for mitogenome analysis. Mitochondrial genomes were sequenced with 454 sequencing technology and were reported in Skonieczna et al. 1 In brief, mitogenomes were amplified in two PCR reactions as described by Fendt et al. 21 Rapid 454 Libraries (Roche Diagnostics GmbH, Mannheim, Germany) of samples were sequenced using Titanium reagents (Roche Diagnostics GmbH) on a GS FLX Sequencer (Roche Diagnostics GmbH). The minority variant detection limit was 1% and the reliability of the mitogenome data was confirmed by phylogenetic analysis. The pathogenicity score of mtDNA mutations was assessed as described by Santorsola et al. 14 
| Statistical analysis
The statistical significance of the differences between the TP53 hereditary or somatic allele frequencies and the presence of somatic mutations (nucleotide substitutions, indels or both) in mitochondrial genomes was calculated using a two-tailed Fisher's exact test. The statistical significance of the differences between the occurrence of somatic TP53 mutations (all or exclusively potentially pathogenic)
and TNM stages was calculated using a Mann-Whitney test.
Statistical analyses were performed using STATISTICA, version 13.1 (StatSoft Inc., Round Rock, TX, USA). Genotype frequencies were tested for Hardy-Weinberg equilibrium using Haploview, version 4.2. 22 The same software was used to determine linkage disequilibrium patterns of neighboring single nucleotide polymorphisms (SNPs).
SNPStats was used to determine haplotypes and check whether their frequencies differed significantly between case (patients with specific clinicopathological outcome or somatic mtDNA mutation) and control (patients without specific clinicopathological outcome or somatic mtDNA mutation) groups. 23 The odds ratios (ORs) and 95% confidence intervals (95% CI) were also calculated. p < 0.05 was considered statistically significant. Bonferroni correction was used to correct for multiple testing. Statistically significant differences are shown in bold.
| RESULTS
The mtDNA variability of normal and cancer samples investigated in the present study was previously described by Skonieczna et al. In the present study, we analysed the TP53 nucleotide sequence of samples, for which the entire mitochondrial genome variability has been described previously. 1 The TP53 sequences were successfully 
| Hereditary TP53 gene mutations
In total, nine polymorphisms were observed in 67 normal specimens of CC patients in the TP53 gene within a sequencing range (see Supporting information, Table S1 ). All of them were known to be variable in human populations (rs745875962, rs17883323, rs1800370, rs1042522, rs1800372, rs34949160, rs1625895, rs12947788 and rs12951053). One of those polymorphisms was a deletion (rs745875962), whereas the others were substitutions (see Supporting information, Table S1 ). Six polymorphisms were Table S3 and Table S4 ).
Somatic mtDNA substitutions (mainly in heteroplasmic state)
were observed in approximately 95% of TP53mut+ CC patients and in approximately 49% of TP53mut-CC patients (see Supporting information, Table S4 ). Only 5% of TP53mut+ and approximately 4% of TP53mut-CC patients harbor at least one homoplasmic somatic substitution in the mitogenome (see Supporting information, Table S4 ).
The somatic mtDNA transition to transversion ratio was similar in
TP53mut+ and TP53mut-cells (approximately 7.5% and 11.5, respectively; see Supporting information, Table S4 ). An A to G transitions occurred approximately three times more frequent in TP53mut+ than TP53mut-cells, although the results were not statistically significant (p > 0.05) (see Supporting information, Table S3 ). The other types of nucleotide changes were similar in TP53mut+ and TP53mut-cells (see Supporting information, Table S3 ). Moreover, in both TP53mut Figure S2 ). In TP53mut+ cells, approximately 5% of all somatic mtDNA mutations that lead to amino acid changes in protein sequences were detected in a homoplasmic state, whereas all synonymous changes were heteroplasmic (see Supporting information, Table   S4 ). By contrast, in TP53mut-cells, all nonsynonymous and synonymous somatic mitogenome mutations were observed in the heteroplasmic state (see Supporting information, Table S4 ). Although the ratio of nonsynonymous to synonymous mtDNA mutation was approximately 2:1 in both TP53mut+ and TP53mut-cells, the median pathogenicity score (according to Santorsola et al. 
| DISCUSSION
Similar to previous observations from other studies on CC, [24] [25] [26] in the present study, we found that somatic indels (all or exclusively in D310 region) and/or substitutions in mitogenomes were not associated with sex, age, tumor location or stage.
The tumour suppressor p53 plays an important role in many cellular processes, such as apoptosis, DNA repair, cell cycle arrest, angiogenesis or mitochondrial quality check. [4] [5] [6] [7] 27 Mutations in the TP53 gene are frequently observed in CC cells, and most of them result in the loss of normal protein function. 19 Because p53 plays a pivotal role in mtDNA maintenance, it was important to determine whether TP53 gene variation is linked to mtDNA mutagenesis. Thus, we carried out a study on TP53 gene variability in CC patients for whom mitogenome sequences were accurately (confirmed by phylogenetic methods) and thoroughly (minority variant detection at the level of 1%) described previously. 1 In the present study, we have focused on a highly mutated region in the TP53 gene that spans exons 3-9. We have shown that somatic but not hereditary TP53 gene mutations are associated with the occurrence of somatic mutations in CC mitogenomes.
To date, the relationship between TP53 and mtDNA somatic mutations in CC has been investigated in only one study that involved Taiwanese patients. 28 Although the abovementioned study showed that TP53 somatic mutations coexisted with somatic mtDNA mutations, the investigation was restricted to the control region, which accounts for only approximately 6% of the entire mtDNA molecule.
Thus, most somatic mtDNA mutations could not have been detected by Chang et al. 26 Indeed, our previous study revealed that only approximately 18% of somatic mtDNA substitutions were located in the control region. 1 Moreover, many of the somatic mtDNA mutations were observed below the 15% level, 1 which is the detection limit of the dideoxy sequencing method. Thus, Chang et al. 26 could have missed many of the somatic mtDNA mutations in their data. By contrast to the study by Chang et al., 26 we have taken into account the sequence variability of the entire mitochondrial genome, for which the minority variant detection limit was set to as low as 1%. Thus, we were able to consider the whole spectrum of mtDNA sequence changes with respect to the TP53 sequence variability in CC patients.
Our analysis has shown the concomitant presence of somatic TP53
and mitogenome mutations in CC patients.
Similar to the present study, Gochaiti et al. Although the presence of somatic mtDNA substitutions in some patients could be linked to the somatic TP53 mutations, it remains to be shown which molecular mechanisms contributed to the occurrence of the somatic mitogenome substitutions in the other individuals.
Indeed, one-half of the patients with somatic mtDNA substitutions had an unchanged TP53 sequence in CC cells. Thus, it is possible that, in those patients, other genes encoding molecules interacting with p53 or participating in mtDNA repair are mutated. Thus, further studies are necessary to completely clarify this issue.
It appears from the present study that sequence variability of the TP53 gene is not associated with somatic indels in CC mitochondrial genomes. It should be noted that the vast majority of somatic mtDNA indels (approximately 96%) were observed within homopolymer regions or microsatellites. 1 Thus, it is probable that they arose as a result of nucleotide errors introduced during replication, such as polymerase gamma slippage. Nevertheless, our previous study excluded the relationship between polymerase gamma variability and length variation of repeated regions in mitogenomes. 22 Therefore, additional research is needed to reveal the molecular background of the length variability in mitochondrial homopolymer regions or microsatellites of CC cells.
The results of the present study should be confirmed further in replication studies because the group of CC patients that was investigated only comprised a small number of individuals.
In the present study, we show that the mutational status of the TP53 
